Avalo Therapeutics, Inc. AVTX
15.47
(0.25)
(1.59%)
as of 25 Sep
- Market cap
- $843.1M
- P/E
- 0.0×
Follow AVTX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (36.27%) | (88.76%) | (72.43%) | 20.97% |
+8 more TTM periods Free account |
|
| (32.50%) | (71.09%) | (58.58%) | 10.56% | ||
ROIC |
(118.21%) | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(25.92%) | (109.20%) | (84.33%) | 11.09% | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(1.57) | (2.97) | (3.84) | (3.73) | |
Free Cash Flow |
(68.29) | (59.69) | (51.46) | (52.26) | |
| Other line items | |||||
Cash ROIC |
(8.04%) | (39.67%) | (28.36%) | (25.71%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.68 | 0.70 | 0.66 | (4.43) | |
Depreciation/Fixed assets |
0.38 | 0.60 | 0.75 | 0.73 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.57) | (2.97) | (3.84) | (3.73) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates